Abstracts 14th ESASO Retina Academy. November 13-15, 2014, Istanbul, Turkey: Abstracts

2014 Ophthalmologica  
To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Methods or Study Design: Prospective randomized clinical trial. We included 20 eyes with treatment-nai¨ve PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3
more » ... hs, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay. Results: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point. Conclusions: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months. Introduction: To evaluate the effect of injection number of ranibizumab on an as-needed treatment regimen during the first year of treatment on the clinical course of neovascular age-related macular degeneration (nAMD). Methods or Study Design: Retrospective study. The newly diagnosed nAMD patients who were treated with intravitreal ranibizumab on an as-needed treatment regimen with a follow-up period of at least 24 months were included in the study. The patients were divided into three groups according to the required injection numbers during the first year; group A, 3 injections; group B, 4-5 injections; group C = 5 injections. Main outcome measures were the change in best corrected visual acuity (BCVA), and central #l thickness (CRT). Secondary outcome measure was the number of injections during the second year. Results: The study included 92 eyes of 87 patients. Group A consisted of 14 eyes (15.2%), group B consisted of 30 eyes (32.6%), and group C consisted of 48 eyes (52.2%). The visual outcomes seemed better in group A; however, there was not a statistically significant difference among the three groups in regards of change in BCVA at all of the time points (p = 0.4 for month 6, p = 0.5 for month 12, p = 0.6 for month 18, p = 0.6 for month 24). There was not a statistically significant difference among the three groups in regards of change in CRT at all of the time points (p = 0.2 for month 6, p = 0.2 for month 12, p = 0.1 for month 18, p = 0.6 for month 24). The mean number of injections at month 12 and 24 was statistically different among the three groups (p < 0.0001 for both). Conclusions: This study showed a possible relationship between injection numbers and treatment outcomes in patients with nAMD on an as-needed treatment regimen. However there was not a statistically significance among the three groups. Abstracts Ophthalmologica 2014;232(suppl 2):1-98 Abstracts Ophthalmologica 2014;232(suppl 2):1-98 Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss in the world. Choroidal neovascularization (CNV) plays the main role in exudative AMD. Major clinical trials have reported the superior efficacy of intravitreal ranibizumab (IVR) treatment. The purpose of the current study was to report the 1-year clinical results of IVR in patients with exudative AMD, and to evaluate whether early treatment is of predictive value for prognosis of the disease. Methods or Study Design: Medical reports of patients who underwent IVR for new-onset exudative AMD between March 2010 and January 2013 at Baskent University School of Medicine Department of Ophthalmology were reviewed retrospectively. All patients were treated with three consecutive monthly IVR and followed up for at least 12 months. Patients were divided into two groups: group 1 consisted of patients with visual symptoms for less than 1 month, and patients who had visual symptoms for 1-3 months were placed in group 2. Results: A total of 104 eyes were involved; there were 40 eyes in group 1 (7-30 days), and 64 eyes in group 2 (35-90 days). The followup time was 13.7 ± 1.9 (12-19) months. The mean logMAR visual acuity (VA) improved, from 0.45 ± 0.639 at baseline to 0.08 ± 0.267 at 12 months in group 1, and from 1.06 ± 0.687 at baseline to 0.75 ± 0.563 at 12 months in group 2. The increase in VA was statistically significant in group 1 (P = 0.009). Mean central retinal thickness (CRT) decreased, from 355.13 ± 119.93 μm at baseline to 250.85 ± 45.48 μm at 12 months in group 1, and from 371.88 ± 91.047 μm at baseline to 268.61 ± 53.51 μm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P = 0.001). Conclusions: Shorter duration of visual symptoms (group 1), was associated with a better visual outcome after treatment. Patients must be informed about self-awareness of visual symptoms.
doi:10.1159/000368726 pmid:25402660 fatcat:amyorasbrvgsnk7st37eosomvy